Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 451 to 500 of 872

TitleReference numberPublishedLast updated
Guidance on the use of coronary artery stentsTA71
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapyTA655
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerTA654
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancerTA653
Pembrolizumab with axitinib for untreated advanced renal cell carcinomaTA650
Naldemedine for treating opioid-induced constipationTA651
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphomaTA649
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)TA648
Avelumab with axitinib for untreated advanced renal cell carcinomaTA645
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)TA646
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)TA647
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphomaTA641
Gilteritinib for treating relapsed or refractory acute myeloid leukaemiaTA642
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643
Entrectinib for treating NTRK fusion-positive solid tumoursTA644
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplantTA640
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancerTA639
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)TA634
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)TA635
Eculizumab for treating refractory myasthenia gravis (terminated appraisal)TA636
Ranibizumab for treating diabetic retinopathy (terminated appraisal)TA637
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedureTA626
Ustekinumab for treating moderately to severely active ulcerative colitisTA633
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancerTA632
Larotrectinib for treating NTRK fusion-positive solid tumoursTA630
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancerTA628
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximabTA629
Lenalidomide with rituximab for previously treated follicular lymphomaTA627
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)TA625
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosisTA624
Patiromer for treating hyperkalaemiaTA623
Sotagliflozin with insulin for treating type 1 diabetesTA622
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)TA618
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedureTA617
Cannabidiol with clobazam for treating seizures associated with Dravet syndromeTA614
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndromeTA615
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumabTA612
Pentosan polysulfate sodium for treating bladder pain syndromeTA610
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal)TA608
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)TA609
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery diseaseTA607
Lanadelumab for preventing recurrent attacks of hereditary angioedemaTA606
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoeaTA605
Idelalisib for treating refractory follicular lymphomaTA604
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA602
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)TA603
Benralizumab for treating severe eosinophilic asthmaTA565
Risankizumab for treating moderate to severe plaque psoriasisTA596
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595

Results per page

  1. 10
  2. 25
  3. 50
  4. All